Deregulated activation of protein tyrosine kinases, such as the epidermal growth factor receptor (EGFR) and Abl, is associated with human cancers including non-small cell lung cancer (NSCLC) and chronic myeloid leukemia (CML). Although inhibitors of such activated kinases have proved to be of therapeutic benefit in individuals with NSCLC or CML, some patients manifest intrinsic or acquired resistance to these drugs.
Introduction
Protein tyrosine kinases play key roles in the regulation of cell proliferation, migration, and survival [1] . Aberrant activity of these enzymes can result from genetic alterations acquired early in tumorigenesis and remains an essential aspect of tumor cell physiology throughout subsequent disease progression [2] . For example, abnormal activation of EGFR Cell culture. Human lung adenocarcinoma PC-9, H1650, and II-18 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum [15] . The human CML cell line K562 as well as immortalized murine bone marrow-derived pro-B cells stably expressing either native human Bcr-Abl ]) [16] were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum.
Flow cytometry. Cells exposed to various agents were harvested by treatment with trypsin, fixed with 70% ethanol, incubated with DNase-free RNase A (100 µg/ml, Sigma), stained with propidium iodide (20 µg/ml), and analyzed for DNA content with the use of a FACSCalibur flow cytometer and Cell Quest Pro software (Becton Dickinson) [17] . For detection of ROS accumulation, cells were incubated for 30 min at 37°C with 10 µM CM-H 2 DCFDA and then monitored for fluorescence as previously described [13, 18] .
Immunoblot analysis. Cell lysates were prepared as described [19, 20] and fractionated by SDS-polyacrylamide gel electrophoresis. The separated proteins were transferred to a polyvinylidene difluoride membrane and probed with primary antibodies and horseradish peroxidase-conjugated secondary antibodies (Promega). Immune complexes were visualized with enhanced chemiluminescence reagents (GE Healthcare Bio-sciences).
Results and Discussion

EGFR mutations are not the only determinant of gefitinib sensitivity in NSCLC cells.
We examined the gefitinib sensitivity of several NSCLC cell lines expressing activated mutant forms of EGFR, including PC-9 (ΔE746-A750 deletion), H1650 (ΔE746-A750), and II-18 (L858R mutation) cells. Although gefitinib inhibited EGFR tyrosine kinase activity (as reflected by EGFR autophosphorylation) in all these NSCLC cells in a concentration-dependent manner, it inhibited the proliferation of PC-9 and II-18 cells but not that of H1650 cells (Fig. 1A) . Furthermore, gefitinib induced a concentration-dependent increase in the proportion of PC-9 cells with a fractional DNA content (cells in sub-G 1 phase), a characteristic feature of apoptosis [17] , without eliciting a similar effect in H1650 or II-18 cells.
At concentrations of ≥ 0.1 µM, gefitinib inhibited the activation of Akt and ERK1/2, major signaling molecules that function downstream of EGFR, as well as induced the activation of caspase-3 in PC-9 cells (Fig. 1B) . In contrast, gefitinib inhibited the activation of ERK1/2 but not that of Akt in II-18 cells, whereas it had no effect on the activation state of ERK1/2 or Akt in H1650 cells. The PI3K-Akt pathway is a major determinant of cell survival [21] , whereas the ERK pathway is a major regulator of cell proliferation [22] . Our results suggest that blockade of both the ERK and PI3K-Akt pathways is required for the induction of apoptosis in the NSCLC cell lines examined.
Gefitinib-induced inhibition of the ERK pathway but not of the PI3K-Akt pathway appeared to result only in suppression of proliferation in II-18 cells. Consistent with this notion, treatment with the combination of the MEK inhibitor PD184352 (10 µM) and the PI3K inhibitor PX-866 (5 µM) to suppress the ERK and PI3K-Akt pathways, respectively, induced apoptosis in all three NSCLC cell lines ( Fig. 2A, B) . (Fig. 3) . It also induced a prominent increase in the proportion of dead cells with a fractional DNA content as well as the activation of caspase-3 in these cells (Fig. 3) . In contrast, imatinib failed to inhibit Bcr-Abl tyrosine kinase activity, the activation of Akt or ERK1/2, or cell proliferation as well as to induce apoptotic cell death or caspase-3 activation in 
Combination of either an ERK pathway or PI3K-Akt pathway inhibitor and an HDAC inhibitor kills cells harboring imatinib-resistant Bcr-Abl
Conclusion
We have shown that the combination of either an ERK pathway inhibitor or a PI3K-Akt pathway inhibitor and a low concentration of an HDAC inhibitor, each of which alone exhibits only marginal apoptosis-inducing activity, efficiently kills NSCLC and CML cells in a manner independent of their sensitivity to EGFR or Abl TKIs, respectively. The efficacy of these drug combinations was greater than that of the combination of ERK pathway and PI3K-Akt pathway inhibitors. We have previously shown that blockade of the ERK pathway [26] or the PI3K-Akt pathway [27] enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the respective signaling pathway is constitutively activated. Co-administration of a cytostatic signaling pathway inhibitor, such as a MEK inhibitor or a PI3K inhibitor, might thus represent a means to achieve safer anticancer strategies through lowering the required dose of cytotoxic anticancer drugs such as HDAC inhibitors or microtubule-destabilizing agents in a wide variety of cancer cells, including those resistant to EGFR or Abl TKIs. Consistent with this notion, optimal use of molecularly targeted therapies has recently been proposed to lie in combination treatment, either with classic cytotoxic drugs or with other targeted therapies [22, 28] . 
